R-006

Risperidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• 經驗公式（希爾表示法）: C₂₃H₂₇FN₄O₂
• CAS號碼: 106266-06-2
• 分子量：: 410.48
• 分類程式碼代碼: 41116107
• NACRES: NA.24

屬性

• 等級: certified reference material
• 形狀: liquid
• 特點: Snap-N-Spike^®/Snap-N-Shoot^®
• 包裝: ampule of 1 mL
• 製造商／商標名: Cerilliant^®
• 濃度: 1.0 mg/mL in methanol
• 技術: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• 應用: clinical testing
• 格式: single component solution
• 儲存溫度: −20°C
• SMILES 字串: CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1
• InChI: 1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
• InChI 密鑰: RAPZEAPATHNIPO-UHFFFAOYSA-N
• 基因資訊: human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

描述

一般說明

Risperidone, marketed as Risperdal^®, Ridal, or Riscalin, is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and irritability in autistic children. This new Certified Snap-N-Spike^® Solution is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, or urine drug testing.

應用

• Vascular Syndromes and Neuroleptic Therapy: RisperiDonesolution has been investigated for its role in inducing severe vascular occlusion-like syndromes in rat models. Research highlights its potential implications for understanding drug-induced vascular problems and testing therapies like BPC 157, a gastric pentadecapeptide with promising therapeutic effects (Strbe et al., 2023).


• UHPLC Method Development: RisperiDoneis a focal point in the development of an advanced UHPLC method using the "Method Operable Design Region" (MODR) approach. This method is designed for the assay and purity determination of risperiDonein various formulations, crucial for maintaining stringent quality controls in pharmaceutical manufacturing (Pawar et al., 2022).


• Optimizing Antipsychotic Dose Regimens: Research incorporates risperiDoneto explore Maximum A Posteriori (MAP) Bayesian modelling, merging drug plasma concentrations and dopamine receptor occupancy. This approach aims to customize antipsychotic dosing to enhance therapeutic outcomes in individual patients, emphasizing personalized medicine in psychiatry (Ismail et al., 2022).


• Antioxidant-mediated Drug Degradation: Studies on risperiDonealso cover the formulation aspects, such as its inclusion in poly(ethylene carbonate) systems to control drug degradation through antioxidant mediation. This research is pivotal in developing sustained-release formulations that enhance drug stability and efficacy (Bohr et al., 2020).


• Patient-reported Outcomes in Schizophrenia Treatment: RisperiDonesolution is studied for its effectiveness in treating schizophrenia, particularly assessing patient-reported outcomes in long-term therapy settings. This research helps gauge patient satisfaction and treatment efficacy, which is essential for optimizing mental health therapies (Dhanda et al., 2019).

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Risperdal is a registered trademark of Johnson & Johnson

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 象形圖: GHS02,GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H225,H301 + H311 + H331,H370
• 防範說明: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• 危險分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• 標靶器官: Eyes,Central nervous system
• 儲存類別代碼: 3 - Flammable liquids
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: 49.5 °F - closed cup
• 閃點（°C）: 9.7 °C - closed cup